This Special Issue is dedicated to neuroendocrine neoplasms (NENs), a category of malignancy that demonstrates wide clinical heterogeneity, posing major challenges in diagnosis and management. There have been significant advances in the field of NEN genomics, pathology, imaging, and treatment over the past five years. NENs are examples of rare tumours (although their incidence and prevalence are increasing) where international collaborative efforts have allowed the generation of high-level evidence to guide optimal patient-centred care. This issue presents both reviews and original papers to provide comprehensive state-of-the-art understanding of this fascinating disease.

To be the best doctor you can be, you need the best information. For more than 90 years, what is now called Goldman-Cecil Medicine has been the authoritative source for internal medicine and the care of adult patients. Every chapter is written by acclaimed experts who, with the oversight of our editors, provide definitive, unbiased advice on the diagnosis and treatment of thousands of common and uncommon conditions, always guided by an understanding of the epidemiology and pathobiology, as well as the latest medical literature. But Goldman-Cecil Medicine is not just a textbook. Throughout the lifetime of each edition, periodic updates continually include the newest information from a wide range of journals. Furthermore, Goldman-Cecil Medicine is available for all users of ClinicalKey, Elsevier's full library of subspecialty textbooks that can be accessed by readers who may want even more in-depth information. - More than 400 chapters authored by a veritable "Who's Who" of modern medicine - A practical, templated organization with an emphasis on evidence-based references - Thousands of algorithms, figures, and tables that make its information readily accessible - Supplemented by over 1500 board-style questions and answers to help you prepare for certification and recertification examinations

In this issue, guest editors bring their considerable expertise to this important topic.Provides in-depth reviews on the latest updates in the field, providing actionable insights for clinical practice. Presents the latest information on this timely, focused topic under the leadership of experienced editors in the field. Authors synthesize

Lung cancer remains a major cause of death in of both women and men in our society. Lung cancer treatment paradigms have changed enormously as we’ve started to understand the genetic complexity and the multiple driver mutations influencing the disease. Therapeutics directed towards, or to inhibit signaling pathways has resulted in increased life spans for our patients. Over the last two decades, we have gone from simple chemotherapy used to treat all, to a personalized medicine approach for the majority. For non-small cell lung cancer patients without driver mutations, the world of immune oncology has arrived. These improved long-term outcomes mean that now our lung cancer patients can live with their cancers, but without progression. The aim of this book is to catalogue the current state of knowledge for the many facets of advanced lung cancer. It describes current treatment approaches for driver mutations, rare mutations, and rare thoracic malignancies such as neuroendocrine tumors. Most importantly, this book addresses the topics of palliative treatment and care which allow our patients to enjoy longer survival with the highest quality of life. We hope you enjoy this e-book. The future is brighter for lung cancer patients and as lung cancer specialists; we finally feel sense optimism about treatment options for our patients.

Up-to-date and evidence-based, Updates on Treatment and Management of Endocrinopathies [correct title?] provides an overview of recent developments regarding the most prevalent endocrine disorders. A concise, easy-to-read reference for endocrinologists and endocrine surgeons, this timely reference includes an overview of each disorder as well as diagnosis, management, treatment, prognosis, and a summary by a renowned expert who has contributed to the most current literature. - Addresses endocrine diseases of the thyroid, parathyroid, and adrenal glands as well as familial endocrine syndromes: multiple endocrine neoplasia type 1 and 2 (MEN). - Includes both surgical and nonsurgical treatments. - Consolidates today's available information on this timely topic into one convenient resource.

This comprehensive subspecialty reference book on NeuroEndocrine Tumor (NET) pathology brings together the diagnostic and clinical expertise of an outstanding team of practicing neuroendocrine pathologists and oncologists. In addition to in-depth coverage of clinico-pathologic aspects of NETs of the various organ systems, the recent histological grading and staging schemes proposed by the North American and European NeuroEndocrine Tumor Societies (NANETS, ENETS), the World Health Organization (WHO) and the American Joint Committee on Cancer (AJCC), this book also focuses on the recent molecular and therapeutic advances in the field of NET pathology and oncology. Neuroendocrine Tumors: Review of Pathology, Molecular and Therapeutic Advances will be an essential reference book for anatomic pathology (histopathology) residents, fellows, surgical pathologists, researchers, oncologists, surgeons and other medical professionals practicing advanced NET Pathology and Oncology in academia, community, private practice and research settings.

This book highlights the increase in thyroid tumors and NET and demonstrates the growing importance of circulating markers in diagnosis as well as treatment and follow-up. Dramatic technical improvements have heightened the clinical impact of well-established, conventional biochemical markers. In addition, more recent genetic and molecular approaches have provided innovative molecular markers. In this context, effective communication between clinicians and laboratory physicians/scientists is essential in allowing all those involved to fully profit from these exciting advances. In this comprehensive, up-to-date book, authors from different laboratory and clinical areas link laboratory and clinical topics. Analytical problems such as interferences, false-negative and false-positive results are discussed in depth, and flow-charts offer insights into identifying and avoiding them. Illustrated clinical cases detail the clinical role and limitations of different tumor markers. Lastly, it explores health technology assessment and economic issues. This is a valuable resource for endocrinologists, oncologists, nuclear medicine physicians, scientists and technologists who want to keep abreast of the latest developments.